Translation in der Nanomedizin. "Qualitative Indikatoren" der medizinischen Innovationsforschung in der Europäischen Union

这个子项目涉及创新的未来评估和创新研究。它定性地检查了旨在评估欧洲纳米医学研究项目的程序的起源、使用和后果，该程序的参与者将其命名为定性指标，即本项目总体框架中所述的非指标。这一程序是由欧盟平台ETPN（欧洲纳米医学技术平台）和欧盟网络enatran（使能纳米医学翻译）带来的。它们的目标是促进和增加整个欧洲纳米医学科学和工业之间的合作。该程序是根据翻译评估（2016-2017）在第一个原型测试阶段的框架内组织的。这个测试阶段是关于建立一个翻译顾问委员会（TAB），由来自不同欧洲国家的选定专家组成，他们应该为评估选定的欧洲研究项目制定一个典型的定性程序。2017年底，在欧洲协调和支持行动NOBEL框架内启动了为期三年（2018-2021）的系统化测试阶段。基于第一阶段测试的结果，TAB专家构建了“定性指标”，他们将这些指标应用于经过申请程序选择的纳米医学研究项目。本子项目对这一过程进行了实证分析，从诺贝尔开始并超越诺贝尔，以下四个步骤：a)构建这些定性指标的方法基础；B)这些指标如何考虑到强制性临床检测的阶段；C)这些指标如何考虑到企业/公司/行业对所评估的研究项目的要求；D)这种定性程序与用于评估纳米医学可持续性的技术创新的基准研究和其他定量指标相比如何。这四个步骤最后回答了这个子项目的框架问题，专家之间的关系如何影响评价程序中定性指标的构建和使用，以及这如何影响欧洲纳米医学的可持续性。

This subproject deals with the future assessment of innovation and innovation research. It qualitatively examines the genesis, usage and consequences of a procedure aiming at evaluating research projects in nanomedicine in Europe on the basis of -- as the actors in this procedure name them -- qualitative indicators, i.e. not-indicators as stated in this project's overarching framework. This procedure has been brought about by the EU platform ETPN (European Technology Platform Nanomedicine) and the EU network ENATRANS (Enabling Nanomedicine Translation). They aim at facilitating and increasing cooperation between science and industry in nanomedicine throughout Europe. This procedure was organised according to the translation assessment (2016-2017) within the framework of a first prototype test phase. This test phase was about building a Translation Advisory Board (TAB) with selected experts from different European countries, who should work on a prototypical qualitative procedure for the evaluation of selected research projects in Europe. At the end of 2017, a systematising test phase has been launched for three years (2018-2021) within the framework of the European Coordination and Support Action NOBEL. Based on the results of the first test phase, the TAB experts construct "qualitative indicators" which they apply to nanomedical research projects selected after an application procedure. This subproject analyses this procedure empirically, starting with and going beyond NOBEL following four steps: a) the methodological basis on which these qualitative indicators are constructed; b) how these indicators take into account the phases of mandatory clinical testing; c) how these indicators take into account the requirements of enterprises/companies/industries in relation to the research projects being evaluated; d) how this qualitative procedure compares to benchmark studies and other quantitative indicators of technological innovation for assessing the sustainability of nanomedicine. These four steps conclude in answering this subproject's framing question, how the relation between experts influences the construction and usage of qualitative indicators in the evaluation procedure and how this affects the sustainability of nanomedicine in Europe.